Leerink Swann Upgrades Endo Pharma (ENDP) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Endo Pharmaceuticals (ENDP) New CEO Is the Real Deal - Jefferies
June 7, 2013 11:02 AM EDTJefferies reiterated a Buy rating and boosted its price target on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from $37 to $45 after CEO Rajiv DeSilva made his 1st public appearance at Jefferies conference Thursday.
Corey Davis comments, "Despite... More
Cantor Fitzgerald Cuts Endo Pharma (ENDP) to Sell; Not Optimistic Restructuring
June 6, 2013 7:14 AM EDTCantor Fitzgerald downgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from Hold to Sell with a price target of $30.00 (from $36.00). Analyst Irina Rivkind is not optimistic about the company's restructuring plans.
"We don't think that a series of small deals, cost-cutting, and improved... More
Jefferies Reiterates Buy on Endo Pharmaceuticals (ENDP) on Restructuring News
June 6, 2013 7:01 AM EDTJefferies reiterated a Buy rating and $37 price target on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) after the company announced a major restructuring Wednesday evening.
Analyst Corey Davis the news comes ahead of schedule and the magnitude of the cost... More
Endo Health (ENDP) Acnnounces Cost Reductions; Will Trim Workforce 15%
June 5, 2013 4:17 PM EDTEndo Health Solutions (Nasdaq: ENDP) today outlined the strategic, operational and organizational steps it is taking to refocus the Company and drive shareholder value. These actions are the result of a comprehensive assessment of Endo's strengths and challenges, its cost structure and execution capabilities, and its most promising opportunities to drive future cash flow and earnings growth. Specifically, the Company announced plans to:
* Reduce annual operating expenses by $325 million
* Explore strategic alternatives for its HealthTronics business and branded pharmaceutical discovery platform
* Improve R&D efficiency and effectiveness, with a focus on development... More
